Benralizumab: Cost-Effective Add-On Therapy for Refractory Eosinophilic Asthma
In patients with refractory eosinophilic asthma, treatment with benralizumab is a cost-effective option to be used as add-on therapy.
Sheila Jacobs
Contributing Writer
Sheila Jacobs is the president of STJ Editorial Services. For more than 25 years, Sheila has been providing writing, fact-checking, and editorial services to numerous clients in the medical education, promotional, and managed care arenas, from the conceptual stage through completion of the final editorial product. Her focus has been in a diverse array of therapeutic areas.
